Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer

Tumours with homologous recombination (HR) defects become sensitive to PARPi. Here, the authors show that androgen receptor (AR) regulates HR and AR inhibition activates the PARP pathway in vivo, thus inhibition of both AR and PARP is required for effective treatment of high risk prostate cancer.

Bibliographic Details
Main Authors: Mohammad Asim, Firas Tarish, Heather I. Zecchini, Kumar Sanjiv, Eleni Gelali, Charles E. Massie, Ajoeb Baridi, Anne Y. Warren, Wanfeng Zhao, Christoph Ogris, Leigh-Anne McDuffus, Patrice Mascalchi, Greg Shaw, Harveer Dev, Karan Wadhwa, Paul Wijnhoven, Josep V. Forment, Scott R. Lyons, Andy G. Lynch, Cormac O’Neill, Vincent R. Zecchini, Paul S. Rennie, Aria Baniahmad, Simon Tavaré, Ian G. Mills, Yaron Galanty, Nicola Crosetto, Niklas Schultz, David Neal, Thomas Helleday
Format: Article
Language:English
Published: Nature Publishing Group 2017-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-017-00393-y

Internet

https://doi.org/10.1038/s41467-017-00393-y

Similar Items